Compliance operations manual, January 1972: a manual of guidelines for implementing the Occupational safety and health act of 1970.

"Changes and additions will be made to the Manual on a continuing basis as determined necessary by experience gained."

Radiation control for health and safety act of 1967. Hearings Ninetieth Congress, first- session [s], on S. 2067, S. 3211, and H.R. 10790 ...

"Serial no. 90-49."

Motor vehicle safety. Hearing before the Surface Transportation Subcommittee of the Committee on Interstate and Foreign Commerce, United States Senate, Eighty-sixth Congress, second session, on H.R. 1341, an act to require passenger-carrying motor vehicles purchased for use by the federal government to meet certain safety standards. June 22, 1960.

Mode of access: Internet.

Captive Primate Safety Act of 2005 : report (to accompany S. 1509).

"June 19, 2006."

Dust of the road : a play in one act /

Mode of access: Internet.

Reauthorization of TEA-21 : hearings before the Subcommittee on Transportation, Infrastructure, and Nuclear Safety and the Committee on Environment and Public Works, United States Senate, One Hundred Seventh Congress, second session, on review of proposals to reauthorize Public Law 105-178, the Transportation Equity Act for the Twenty-First Century.

Shipping list nos.: 2004-0089-P (pt. 1), 2004-0088-P (pt. 2).

The seamen's bill. (Life boat equipment) Hearings held before the Committee on the merchant marine and fisheries, House of Representatives, on S. 136, an act to promote the welfare of American seamen in the merchant marine of the United States; to abolish arrest and imprisonment as a penalty for desertion and to secure the abrogation of treaty provisions in relation thereto: and to promote safety at sea. Hearings of December 13, 15, 16, 17, 18, and 19, 1913.

Joshua W. Alexander, Chairman.

Clean Air Act : ozone and particulate matter standards : hearings before the Subcommittee on Clean Air, Wetlands, Private Property, and Nuclear Safety and the Committee on Environment and Public Works, United States Senate, One Hundred Fifth Congress, first session.

Shipping list no.: 98-0052-P (pt. 1), 98-0155-P (pt. 2).

Occupational safety and health act [microform] : report

Reuse of record except for individual research requires license from Congressional Information Service, Inc.

Federal metal and nonmetallic mine safety act. Hearings before the Select Subcommittee on Labor of the Committee on Education and Labor, House of Representatives, Eighty-ninth Congress, first session, on H. R. 6961 and similar bills, a bill to promote health and safety in metal and nonmetallic mineral industries, and for other purposes.

Adam C. Powell, chairman.

Tamang v Act Security 2012

Case law report - online

Road user attitudes and the safety of cyclists

DUE TO COPYRIGHT RESTRICTIONS ONLY AVAILABLE FOR CONSULTATION AT ASTON UNIVERSITY LIBRARY AND INFORMATION SERVICES WITH PRIOR ARRANGEMENT

The value of corporate reputation and the Defamation Act 2013:a brave new world or road to ruin?

Questions whether the focus on freedom of expression under the Defamation Act 2013 could undermine the value of corporate reputation as a commercial asset.

A study of the effects of the Comprehensive Occupational Safety and Health Reform Act (H.R. 1280).

"April 1994."

Predictive Value Of Phase I Trials For Safety In Later Trials And Final Approved Dose: Analysis Of 61 Approved Cancer Drugs.

Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safety of new agents. We compared data from phase I and registration trials to determine whether early trials predicted later safety and final dose. We searched the U.S. Food and Drug Administration (FDA) website for drugs approved in nonpediatric cancers (January 1990-October 2012). The recommended phase II dose (R2PD) and toxicities from phase I were compared with doses and safety in later trials. In 62 of 85 (73%) matched trials, the dose from the later trial was within 20% of the RP2D. In a multivariable analysis, phase I trials of targeted agents were less predictive of the final approved dose (OR, 0.2 for adopting ± 20% of the RP2D for targeted vs. other classes; P = 0.025). Of the 530 clinically relevant toxicities in later trials, 70% (n = 374) were described in phase I. A significant relationship (P = 0.0032) between increasing the number of patients in phase I (up to 60) and the ability to describe future clinically relevant toxicities was observed. Among 28,505 patients in later trials, the death rate that was related to drug was 1.41%. In conclusion, dosing based on phase I trials was associated with a low toxicity-related death rate in later trials. The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials.